Efficacy and safety of allopurinol in the treatment of chronic kidney disease: a meta-analysis
10.3760/cma.j.cn431274-20210421-00468
- VernacularTitle:别嘌呤醇治疗慢性肾脏病疗效和安全性的meta分析
- Author:
Shunyao LIU
1
;
Jing E
;
Hongyan LUO
;
Li BAO
;
Wenzhu TIAN
;
Xi BAO
;
Shilu CAO
;
Yali ZHENG
Author Information
1. 宁夏医科大学，银川 750000
- Keywords:
Renal insufficiency, chronic;
Allopurinol;
Meta-analysis
- From:
Journal of Chinese Physician
2022;24(4):505-511
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of allopurinol in the treatment of chronic kidney disease.Methods:The databases of Embase, PubMed and the Cochrane library were searched for randomized controlled trials of allopurinol in patients with chronic kidney disease. According to the Cochrane system evaluation method, two evaluators independently screened the literature and extracted the data, and analyzed the results with Revman 5.3 software.Results:Finally, 10 articles were included, including 940 patients (472 in the experimental group and 468 in the control group). Meta analysis showed that allopurinol treatment could reduce blood uric acid ( MD=-2.40, 95% CI: -2.74--2.05, P<0.01), 24-hour urinary protein ( MD=-0.61, 95% CI: -1.17--0.06, P=0.03) and increase estimation of glomerular filtration rate(eGFR) ( MD=2.51, 95% CI: 1.86-3.17, P<0.01). There was no significant difference in adverse events between the experimental group and the control group ( OR=1.40, 95% CI: 0.61-3.19, P=0.42), but allopurinol treatment could reduce the risk of cardiovascular events ( OR=0.58, 95% CI: 0.38-0.89, P=0.01). Conclusions:Allopurinol treatment of chronic kidney disease can reduce urinary protein, improve eGFR, and reduce the risk of cardiovascular events.
